UBS biotech analyst Matthew Roden, PhD. listed his favorite biotech stocks for 2014 and boosted his price targets on a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE